Plenty of reason to not do a Brilacidin deal now.
Post# of 72444
IPIX with the following will be able to negotiate a significantly better deal on the Brilacidin platform (or buyout):
$300M in the bank
B ABSSSI Phase 3 in progress and paid
B OM Phase 3 in progress and paid
B UP Phase 2b in progress and paid
Alternatively, if Prurisol puts up some killer numbers (40%PASI75@300mg) it might be worth doing the quick B deal and retaining much larger ownership of an oral psoriasis drug that will generate tens of billions over it's patent life.
All that said, I agree with you and think the odds of a total takeout this year are are as high as any partnership. Looking for $8-30/share depending on how Prurisol does and how pleased BP actually is with the K 2a data.
Go IPIX!

